Testing for COVID-19 antibodies among UZ Brussel employees after vaccination
SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following COVID-19 Vaccination Using an Adenoviral Vector
This study is testing how well the COVID-19 vaccine works in creating antibodies among UZ Brussel employees who have been vaccinated.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Universitair Ziekenhuis Brussel Academic / other |
| Locations | 1 site (Brussels) |
| Trial ID | NCT04939402 on ClinicalTrials.gov |
What this trial studies
This study investigates the seroprevalence and seroconversion of SARS-CoV-2 antibodies among employees of UZ Brussel who received the ChAdOx1 nCoV-19 vaccine. Employees presenting symptoms suggestive of COVID-19 will undergo real-time PCR testing, and serological tests will be performed to assess antibody levels. The study aims to determine the effectiveness of the vaccine in generating an immune response and its potential role in protecting against reinfection. The findings could provide valuable insights into the vaccine's efficacy among healthcare workers.
Who should consider this trial
Good fit: Ideal candidates for this study are adult employees of UZ Brussel who received the ChAdOx1 nCoV-19 vaccine during the specified period.
Not a fit: Patients who are not active employees of UZ Brussel during the inclusion period will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of vaccine-induced immunity and inform future vaccination strategies.
How similar studies have performed: Other studies have shown success in assessing serological responses to COVID-19 vaccines, indicating that this approach is supported by existing research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any adult employee of the UZ Brussel at T1 who has been vaccinated at the UZ Brussel with ChAdOx1 nCoV-19 vaccine between the 2nd of March and the 9th of March 2021 after participating to phase 4 of the COVEMUZ study between the 25th of January and the 12th of February and has provided a signed informed consent. Exclusion Criteria: * UZ Brussel employees not active during the inclusion period (T1).
Where this trial is running
Brussels
- UZ Brussel — Brussels, Belgium (Recruiting)
Study contacts
- Study coordinator: Sabine Allard, phd, md
- Email: sabine.allard@uzbrussel.be
- Phone: +32 2 477
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.